(BRK.A), (BRK.B)
Berkshire Hathaway Specialty Insurance (BHSI) has unveiled a new Management Liability Insurance Policy designed specifically for Life Science, Biotech, and Pharmaceutical (LBP) companies in Australia. The policy addresses the unique risks faced by this fast-growing sector, particularly early-stage and R&D-focused businesses.
“The new LBP Management Liability Policy reflects our commitment to Australia’s thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey,” said Jessica Jefferies, Underwriting Manager at BHSI Australia.
The policy offers enhanced coverage not typically included in standard management liability products. It protects Directors, Officers, and members of Scientific and Medical Advisory Boards, and includes critical features such as coverage for private capital raisings and protection in the event of company insolvency. Importantly, it also offers options to extend coverage to U.S. exposures, acknowledging the common pursuit of FDA approvals by Australian firms.
This launch builds on BHSI’s strong position in the Directors and Officers insurance market for ASX-listed life sciences companies and supports its broader strategy to deliver tailored solutions across the life sciences value chain—from start-up to scale.
© 2025 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.